Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + cytarabine + etoposide
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Pv-R CYVE 1 + Pv-R CYVE 2 is a chemoimmunotherapy regimen consisting of two cycles of polatuzumab vedotin, rituximab, cytarabine, and etoposide. It is primarily investigated for the treatment of mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL) in children, adolescents, and young adults. The regimen integrates the targeted anti-CD79b antibody-drug conjugate polatuzumab vedotin and the anti-CD20 monoclonal antibody rituximab with the cytotoxic agents cytarabine (a pyrimidine analog) and etoposide (a topoisomerase II inhibitor). This combination aims to provide robust disease control while facilitating a reduction in anthracycline exposure and radiation therapy, thereby mitigating long-term toxicities in younger patient populations. The regimen is a key component of clinical trials sponsored by New York Medical College.
- Brand names
- PolivyRituxanCytosar-UVepesid
- Other names
- Pv-R CYVE 1 + Pv-R CYVE 2Pola-R-CYVE
02
Targets
TOP2A (DNA topoisomerase II)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + cytarabine + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + cytarabine + etoposide.